LINC02057 as a potential tumor marker for the aggressive renal cell carcinoma

Renal cell carcinoma (RCC) is a common urological malignancy with a favorable prognosis in early tumor stages. However, metastatic RCC exhibits low survival rates due to late-stage diagnoses. Thus, it is essential to investigate the molecular biology of RCC progression to develop effective tumor markers. Long non-coding RNAs (lncRNAs) play significant roles in regulating molecular mechanisms associated with RCC progression. This study evaluates LINC02057 expression levels in RCC patients to propose it as a potential tumor marker.

Fresh tissues were collected from fifty RCC patients. LINC02057 expression levels were evaluated in tumor tissues versus normal margins via Real-time PCR to explore potential associations with RCC clinicopathological features.

There were significant higher levels of LINC02057 expressions in high-grade (III/IV) tumor compared with low-grade tumors (p = 0.017). Early stage (T1/2) tumors had significant lower levels of LINC02057 expressions compared with advanced stage (T3/4) tumors in female RCC patients (p = 0.042). There was positive correlation between expression level of LINC02057 and tumor size in patients older than 60 years old (p = 0.046).

High-grade tumors with advanced stages have a high metastatic potential. Therefore, LINC02057 can be suggested as a potential marker for prediction of tumor aggressiveness among RCC patients.